Back to top

LACOG 0213 – AUGMENT

  /    /  LACOG 0213 – AUGMENT

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/RefractoryIndolent Lymphoma.

Type of Study: Clinical Trial

Sponsor / Support: Celgene

Primary Objectives: To evaluate the efficacy and safety of rituximab plus lenalidomide combination therapy insubjects with relapsed/refractoryindolent lymphoma

Design: This Phase 3 multicenter, double-blind, randomized study is designed to evaluate the efficacy and safety of rituximab plus lenalidomide versus rituximab plus placebo.

Sample Size: 350 patients

Principal Investigator: Phillip Scheinberg

Countries LATAM: Brazil